About Catalent (NYSE:CTLT)
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.
Industry, Sector and Symbol
Trailing P/E Ratio27.21
Forward P/E Ratio26.66
Sales & Book Value
Annual Sales$2.08 billion
Price / Sales2.49
Cash Flow$2.59 per share
Price / Cash15.00
Book Value$7.82 per share
Price / Book4.98
Net Income$109.80 million
Return on Equity23.97%
Return on Assets5.24%
Frequently Asked Questions for Catalent (NYSE:CTLT)
What is Catalent's stock symbol?
Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."
How were Catalent's earnings last quarter?
Catalent, Inc. (NYSE:CTLT) issued its quarterly earnings results on Monday, November, 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.01. The firm had revenue of $543.90 million for the quarter, compared to analyst estimates of $490.75 million. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The company's revenue was up 23.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.16 EPS. View Catalent's Earnings History.
When will Catalent make its next earnings announcement?
Where is Catalent's stock going? Where will Catalent's stock price be in 2017?
8 analysts have issued 12-month price objectives for Catalent's shares. Their predictions range from $25.00 to $50.00. On average, they expect Catalent's stock price to reach $41.38 in the next year. View Analyst Ratings for Catalent.
What are Wall Street analysts saying about Catalent stock?
Here are some recent quotes from research analysts about Catalent stock:
- 1. According to Zacks Investment Research, "Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. " (11/6/2017)
- 2. Jefferies Group LLC analysts commented, "The promise of stability offered by CTLT's diversified revenue stream and LT contracts has been thwarted by FX headwinds, the Beinheim shutdown, and overstocking by DDS segment client. Currency movements are hard to predict or avoid, but management believes the latter two are history. Tuck-in M&A remains a focus to augment mid-single digit revenue growth. We increase estimates and PT slightly. Remain at Hold." (2/27/2017)
Who are some of Catalent's key competitors?
Some companies that are related to Catalent include Dr. Reddy's Laboratories Ltd (RDY), Valeant Pharmaceuticals International (VRX), Patheon N.V. (PTHN), Taro Pharmaceutical Industries (TARO), Akorn (AKRX), BTG plc (BTG), Opko Health (OPK), Hikma Pharmaceuticals PLC (HIK), Horizon Pharma PLC (HZNP), Amicus Therapeutics (FOLD), Corcept Therapeutics Incorporated (CORT), Pacira Pharmaceuticals (PCRX), Emergent Biosolutions (EBS), Cambrex Corporation (CBM), Theravance Biopharma (TBPH), Innoviva (INVA), Impax Laboratories (IPXL) and Akcea Therapeutics (AKCA).
Who are Catalent's key executives?
Catalent's management team includes the folowing people:
- John R. Chiminski, Chairman of the Board, President, Chief Executive Officer (Age 53)
- Matthew M. Walsh CPA, Chief Financial Officer, Executive Vice President (Age 51)
- Aristippos Gennadios Ph.D., President - Softgel Technologies (Age 52)
- Wetteny Joseph, President - Clinical Supply Services (Age 45)
- Barry B. Littlejohns, President - Drug Delivery Solutions (Age 51)
- Steven L. Fasman, Senior Vice President, General Counsel and Corporate Secretary (Age 55)
- William Downie, Senior Vice President - Global Marketing & Sales (Age 50)
- Lance Miyamoto, Senior Vice President - Global Human Resources (Age 62)
- Christine Dolan, Senior Vice President - Product Development (Age 49)
- Scott Gunther, Senior Vice President - Quality & Regulatory Affairs (Age 50)
Who owns Catalent stock?
Catalent's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (4.86%), Schroder Investment Management Group (3.29%), JPMorgan Chase & Co. (3.24%), Earnest Partners LLC (1.93%), Macquarie Group Ltd. (1.65%) and Brown Advisory Inc. (1.47%). Company insiders that own Catalent stock include Blackstone Management Associat, Christine Dolan, Donald E Morel, Jr, John R Chiminski, Matthew M Walsh, Sharon Johnson and Uwe Roehrhoff. View Institutional Ownership Trends for Catalent.
Who sold Catalent stock? Who is selling Catalent stock?
Catalent's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Schroder Investment Management Group, Janus Henderson Group PLC, Prudential Financial Inc., Ameriprise Financial Inc., Norris Perne & French LLP MI, Cubist Systematic Strategies LLC and Artemis Investment Management LLP. Company insiders that have sold Catalent company stock in the last year include Christine Dolan, John R Chiminski and Sharon Johnson. View Insider Buying and Selling for Catalent.
Who bought Catalent stock? Who is buying Catalent stock?
Catalent's stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, Macquarie Group Ltd., Allianz Asset Management GmbH, Three Peaks Capital Management LLC, Bank of New York Mellon Corp and Schwab Charles Investment Management Inc.. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.
How do I buy Catalent stock?
Shares of Catalent can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Catalent's stock price today?
One share of Catalent stock can currently be purchased for approximately $38.92.
How big of a company is Catalent?
Catalent has a market capitalization of $5.17 billion and generates $2.08 billion in revenue each year. The company earns $109.80 million in net income (profit) each year or $0.87 on an earnings per share basis. Catalent employs 10,800 workers across the globe.
How can I contact Catalent?
Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]
MarketBeat Community Rating for Catalent (CTLT)MarketBeat's community ratings are surveys of what our community members think about Catalent and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Catalent (NYSE:CTLT) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 3 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.63)|
|Consensus Price Target: ||$41.38 (6.31% upside)|
Consensus Price Target History for Catalent (NYSE:CTLT)
Analysts' Ratings History for Catalent (NYSE:CTLT)
(Data available from 11/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/7/2017||Piper Jaffray Companies||Boost Price Target||Overweight||$45.00 -> $50.00||N/A|
|10/23/2017||Needham & Company LLC||Reiterated Rating||Hold||N/A|
|9/21/2017||Morgan Stanley||Upgrade||Equal Weight -> Overweight||$29.00 -> $48.00||High|
|9/20/2017||Bank of America Corporation||Reiterated Rating||Buy||$40.00 -> $45.00||Low|
|9/20/2017||Wells Fargo & Company||Boost Price Target||Outperform||$39.00 -> $43.00||Low|
|8/29/2017||William Blair||Reiterated Rating||Ourperform||High|
|8/29/2017||Jefferies Group LLC||Reiterated Rating||Hold||$35.00 -> $38.00||High|
|8/29/2017||J P Morgan Chase & Co||Reiterated Rating||Buy||$40.00||High|
|12/1/2016||Goldman Sachs Group, Inc. (The)||Initiated Coverage||Neutral||$25.00||N/A|
|2/10/2016||Deutsche Bank AG||Lower Price Target||Hold||$31.00 -> $24.00||N/A|
|12/9/2015||Raymond James Financial, Inc.||Downgrade||Outperform -> Market Perform||N/A|
Earnings History and Estimates Chart for Catalent (NYSE:CTLT)
Earnings History by Quarter for Catalent (NYSE CTLT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/6/2017||Q1 2018||$0.20||$0.21||$490.75 million||$543.90 million||View||N/A|
|8/28/2017||Q4 2017||$0.57||$0.65||$547.48 million||$616.90 million||View||N/A|
|5/4/2017||Q3 2017||$0.36||$0.38||$470.95 million||$532.60 million||View||Listen|
|2/6/2017||Q217||$0.27||$0.27||$474.07 million||$483.70 million||View||Listen|
|11/7/2016||Q117||$0.13||$0.16||$430.26 million||$442.20 million||View||Listen|
|8/29/2016||Q416||$0.53||$0.52||$498.06 million||$532.20 million||View||Listen|
|5/4/2016||Q316||$0.31||$0.20||$425.92 million||$438.00 million||View||N/A|
|2/9/2016||Q216||$0.34||$0.36||$441.99 million||$454.90 million||View||N/A|
|11/3/2015||Q116||$0.21||$0.14||$407.80 million||$423.00 million||View||N/A|
|9/2/2015||Q415||$0.58||$0.60||$496.91 million||$510.10 million||View||N/A|
|5/5/2015||Q3 2015||$0.43||$0.46||$453.25 million||$446.60 million||View||N/A|
|2/11/2015||Q215||$0.33||$0.44||$451.40 million||$455.80 million||View||N/A|
|11/13/2014||Q314||$0.20||$0.13||$411.20 million||$418.30 million||View||N/A|
Earnings Estimates for Catalent (NYSE:CTLT)
Current Year EPS Consensus Estimate: $1.46 EPS
Next Year EPS Consensus Estimate: $1.67 EPS
Dividend History for Catalent (NYSE:CTLT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Catalent (NYSE CTLT)
Insider Ownership Percentage: 1.70%
Institutional Ownership Percentage: 94.69%
Insider Trades by Quarter for Catalent (NYSE CTLT)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/21/2017||Uwe Roehrhoff||Director||Buy||7,500||$39.22||$294,150.00|| |
|8/29/2017||Christine Dolan||SVP||Sell||1,594||$38.75||$61,767.50|| |
|8/1/2017||Christine Dolan||SVP||Sell||745||$34.85||$25,963.25|| |
|4/25/2017||Sharon Johnson||Insider||Sell||9,160||$29.00||$265,640.00|| |
|3/20/2017||John R. Chiminski||Insider||Sell||73,819||$28.62||$2,112,699.78|| |
|2/15/2017||Donald E. Morel, Jr.||Director||Buy||10,000||$29.27||$292,700.00|| |
|9/9/2016||Blackstone Management Associat||Major Shareholder||Sell||17,100,705||$23.58||$403,234,623.90|| |
|6/9/2016||Blackstone Management Associat||Major Shareholder||Sell||8,785,539||$24.51||$215,333,560.89|| |
|5/27/2016||Matthew M Walsh||Insider||Sell||21,197||$28.85||$611,533.45|| |
|8/19/2015||John R Chiminski||Insider||Sell||38,505||$33.81||$1,301,854.05|| |
|8/17/2015||John R Chiminski||Insider||Sell||35,550||$33.80||$1,201,590.00|| |
|7/20/2015||John R Chiminski||Insider||Sell||33,081||$29.40||$972,581.40|| |
|7/6/2015||John R Chiminski||Insider||Sell||33,828||$29.34||$992,513.52|| |
|6/11/2015||Blackstone Management Associat||Major Shareholder||Sell||1,844,963||$28.13||$51,898,809.19|| |
|6/8/2015||Blackstone Management Associat||Major Shareholder||Sell||12,299,753||$28.13||$345,992,051.89|| |
|4/1/2015||Scott Houlton||Insider||Sell||16,253||$30.61||$497,504.33|| |
|3/27/2015||Stephen Leonard||Insider||Sell||31,005||$30.13||$934,180.65|| |
|2/17/2015||Scott Houlton||Insider||Sell||14,538||$27.50||$399,795.00|| |
|2/13/2015||Scott Houlton||Insider||Sell||1,400||$28.28||$39,592.00|| |
Latest Headlines for Catalent (NYSE CTLT)
Catalent (NYSE CTLT) Chart for Thursday, November, 23, 2017